A review of economic evaluations of 13-valent pneumococcal conjugate vaccine (PCV13) in adults and the elderly
Authors:
Open Access
- 3 April 2015
- journal article
- review article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 11 (4) , 818-825
Abstract
The 13-valent pneumococcal conjugated vaccine (PCV13) is already recommended for some adult groups and is being considered for wider use in many countries. In order to identify the strengths and limitations of the existing economic evaluation studies of PCV13 in adults and the elderly a literature review was conducted. The majority of the studies identified (9 out of 10) found that PCV13 was cost-effective in adults and/or the elderly. However, these results were based on assumptions that could not always be informed by robust evidence. Key uncertainties included the efficacy of PCV13 against non-invasive pneumonia and the herd immunity effect of childhood vaccination programs. Emerging trial evidence on PCV13 in adults from the Netherlands offers the ability to parameterize future economic evaluations with empirical efficacy data. However, it is important that these estimates are used thoughtfully when they are transferred to other settings.Keywords
This publication has 39 references indexed in Scilit:
- Budget impact analysis of a pneumococcal vaccination programme in the 65-year-old Spanish cohort using a dynamic modelBMC Infectious Diseases, 2013
- Vaccination of risk groups in England using the 13 valent pneumococcal conjugate vaccine: economic analysisBMJ, 2012
- Serotype replacement in disease after pneumococcal vaccinationThe Lancet, 2011
- Results of a cohort model analysis of the cost-effectiveness of routine immunization with 13-valent pneumococcal conjugate vaccine of those aged ≥65 years in the NetherlandsClinical Therapeutics, 2010
- Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate VaccineThe Journal of Infectious Diseases, 2010
- Immunological responses to pneumococcal vaccine in frail older peopleVaccine, 2009
- Initial and Subsequent Response to Pneumococcal Polysaccharide and Protein‐Conjugate Vaccines Administered Sequentially to Adults Who Have Recovered from Pneumococcal PneumoniaThe Journal of Infectious Diseases, 2008
- Comparison of Pneumococcal Conjugate Polysaccharide and Free Polysaccharide Vaccines in Elderly Adults: Conjugate Vaccine Elicits Improved Antibacterial Immune Responses and Immunological MemoryClinical Infectious Diseases, 2008
- Immunogenicity of varying dosages of 7-valent pneumococcal polysaccharide–protein conjugate vaccine in seniors previously vaccinated with 23-valent pneumococcal polysaccharide vaccineVaccine, 2007
- An Introduction to Markov Modelling for Economic EvaluationPharmacoEconomics, 1998